O

OraSure Technologies

Develops and commercializes oral-fluid diagnostic tests

International Logistics Specialist

Full-TimeUpdated on 10/23/2026
$51k - $88k/yr+ Employee referral cash bonus
Mid, Senior
Bachelor's
Bethlehem, PA, USA
HybridHybrid in Bethlehem, PA; travel may include local sites within 10 miles and limited travel to other company locations or external partners.
Operations & LogisticsLogistics & Transportation

About the job

Requirements
  • A bachelor's degree in Logistics, International Business, or a related field is required.
  • At least 3–5 years of experience in international logistics or a related field is required.
  • A reliable, high-speed internet connection is necessary for remote work.
  • Well-developed knowledge of Microsoft Office, including Outlook, Word, Excel, and PowerPoint, is required; familiarity with SharePoint, OneDrive, and Teams is expected.
  • Proficiency in freight-forwarding software and logistics management systems is required.
  • Strong understanding of international trade regulations and customs procedures, including proficiency in preparing international shipping documentation, is required.
  • Knowledge of customs clearance procedures and duty and tax analysis is required.
  • In-depth technical knowledge of trade compliance principles, including customs valuation, Incoterms, licenses and permits, country of origin, Harmonized Tariff Schedule classifications, duty optimization and Free Trade Agreements, export controls, and sanctions, is required.
  • Strong attention to detail and compliance with shipping regulations is required.
  • Ability to work independently and collaboratively in a fast-paced environment, with analytical, organizational, and problem-solving skills, is required.
  • Comprehensive knowledge of international logistics, shipping regulations, customs procedures, freight forwarding, and supply chain management is required, including staying informed about changes in global trade laws and compliance requirements.
  • Ability to manage international shipping documentation accurately and ensure completeness and customs compliance is required.
  • Ability to coordinate international supply chain activities with suppliers, carriers, customs brokers, and internal teams is required.
  • Ability to resolve international shipment issues such as customs delays, transportation problems, or documentation errors and proactively minimize disruptions is required.
  • Ability to communicate with internal teams, external partners, and global stakeholders and maintain relationships with carriers, customs authorities, and other relevant parties is required.
  • Travel may be required to local Bethlehem sites within a 10-mile radius, with limited additional travel for meetings, training, audits, or collaboration.
Responsibilities
  • Verify required terms of sale, including Incoterms.
  • Accommodate customer requests while ensuring profitability, and obtain carrier rate quotes as required.
  • Maintain professional working relationships with carriers and partners.
  • Compare and negotiate rates to determine cost-efficiency, competitiveness, and service quality.
  • Create pro forma invoices linked to payment processes and used to secure official purchase orders.
  • Enter relevant sales order documentation into SAP.
  • Coordinate product availability and storage with Production and Planning.
  • Prepare or coordinate international import and export documentation, including Shipper's Letter of Instruction, Commercial Invoice, Packing List, Certificate of Origin, Automated Export System filing, Certificate of Analysis, pre-shipment inspection and sampling, Letter of Credit, Bill of Lading, Declaration of Conformity, Letter of Export, and country-specific documents such as ISO and GMP certificates and manufacturer's declarations.
  • Track shipments in process through delivery to their end destinations.
  • Serve as the primary customer contact for order placement, inquiries, and proactive shipment management to support on-time delivery and customer satisfaction.
  • Coordinate customer shipments with freight forwarders, carriers, customs brokers, inspection agencies, and other third parties, and provide contingency plans when needed.
  • Assign Harmonized Tariff Schedule codes based on customs regulations and product data.
  • Facilitate and track shipments from manufacturing through final delivery, and assist with duty and tax analysis.
  • Resolve customs clearance issues with carriers and brokers and assist with customer regulatory requirements as requested.
  • Perform additional logistics and customer care duties as requested.
  • Resolve conflicts and coordinate with production and sales to accommodate customer availability requests and align with sales forecasts and date-specific departmental and organizational goals.
  • Fulfill promotional marketing requests from Sales and Marketing and maintain account management for major customer accounts.
  • Assist with audits as needed.
Desired Qualifications
  • SAP knowledge is preferred.

About the company

OraSure Technologies focuses on creating simple, accessible diagnostic tools and sample-collection systems for infectious diseases. Its core products include rapid tests and molecular diagnostics that use oral-fluid specimens, such as the OraQuick at-home HIV test, and collection devices from DNA Genotek. The company builds end-to-end solutions by combining easy-to-use tests with reliable specimen collection, enabling testing at home, in clinics, or in the field. What sets OraSure apart is its long history of FDA-approved oral-fluid diagnostics and a strategy that blends product development with targeted acquisitions (e.g., DNA Genotek, Sherlock Biosciences) to cover collection, processing, and analysis. The goal is to expand access to accurate, rapid testing for infectious diseases, making diagnostics more convenient and broadly available.

Company Size

201-500

Company Stage

IPO

Headquarters

Bethlehem, Pennsylvania

Founded

1987

Get referred to OraSure Technologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $30.6 million, beating guidance and rising 10% sequentially.
  • Gross margin improved to 43.5% in Q2 2026, supporting profitability targets for 2027.
  • Altai truce through March 31, 2027 and a declassified board reduce governance distraction.

What critics are saying

  • Core revenue stayed flat year over year in Q2 2026, limiting turnaround credibility.
  • OraSure withdrew its CT/NG 510(k) in July 2026, pushing commercialization into a later filing.
  • NowDiagnostics trial starts January 17, 2027; trade-secret exposure threatens DNA Genotek’s moat.

What makes OraSure Technologies unique

  • OraSure pairs home diagnostics with DNA Genotek sample stabilization and collection technology.
  • June 2026 Colli-Pee Dx cleared Roche cobas STI workflows for private at-home urine collection.
  • July 2026 Ebola 2.0 EUA extends OraQuick across all four human Ebola viruses.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Parental Leave
  • Mental Health Support
  • Training Programs

Growth & Insights and Company News

6 month growth

0%

1 year growth

-4%

2 year growth

-5%
U.S. Securities and Exchange Commission
Sep 19th, 2026
8-K

Date of Report (Date of earliest event reported): December 19, 2024

Yahoo Finance
Aug 6th, 2026
OraSure Q2 revenue climbs 9.7% to $30.6M, FDA clears STI test as firm targets 2027 profitability

OraSure Technologies reported second-quarter revenue of $30.6 million, up 9.7% sequentially and exceeding guidance. Diagnostic-products revenue rose 14.7% whilst sample-management revenue grew 9%, driven by stronger public-health demand, syphilis testing, and Sickle SCAN. The company achieved regulatory milestones including FDA clearance for its Colli-Pee Dx STI urine-collection kit and Emergency Use Authorisation for the OraQuick Ebola 2.0 test. However, it delayed the expected 2026 US launch of its IntelliQuick CT/NG test. Gross margin improved to 43.5%. OraSure ended the quarter debt-free with $161 million in cash. Management forecast third-quarter revenue of $29.5 million to $32.5 million and continues targeting operating cash-flow break-even entering 2027.

Associated Press
Jul 21st, 2026
OraSure receives FDA emergency use authorization for second-generation Ebola test

OraSure Technologies has received Emergency Use Authorization from the US Food and Drug Administration for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The test can detect all four Ebola viruses known to cause disease in humans using whole blood or cadaveric oral fluid, with results available in 30 minutes. The second-generation test features increased sensitivity and new chemistry compared to the original version, which received full FDA authorisation in 2019. Development was supported by the Biomedical Advanced Research and Development Authority under a 2022 contract. The authorisation comes as Central Africa faces a serious Ebola outbreak centred in the Democratic Republic of the Congo, which has prompted the World Health Organisation to declare a global public health emergency. OraSure is ramping up production to meet potential demand.

Associated Press
Jun 11th, 2026
OraSure gains FDA clearance for at-home STI test collection kit compatible with Roche systems

OraSure Technologies has received FDA clearance for its Colli-Pee Dx Urine Collection Kit, enabling at-home testing for sexually transmitted infections including chlamydia, gonorrhoea, trichomonas and mycoplasma genitalium. The kit works with Roche's cobas molecular diagnostic systems. The device uses proprietary stabilisation technology to maintain urine sample integrity at ambient temperatures, allowing patients to collect first-void urine samples privately at home. Healthcare providers can prescribe the kit, and laboratories can process specimens using Roche's automated platforms. The clearance expands access for individuals with mobility or geographical constraints and enables population-level screening programmes. OraSure subsidiary DNA Genotek will sell the kit, supporting high-volume molecular STI testing through a validated mail-in workflow.

GlobeNewswire
Jun 11th, 2026
OraSure Technologies, Inc. announces FDA clearance that expands patient-friendly access to testing for sexually transmitted infections.

OraSure Technologies, Inc. announces FDA clearance that expands patient-friendly access to testing for sexually transmitted infections. The clearance combines OraSure's Colli-Pee(TM)- Dx Urine Collection Kit for at-home sample collection with Roche's cobas(R) molecular lab testing equipment. BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) - OraSure Technologies, Inc. ("OraSure") (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today announced U.S. Food and Drug Administration (FDA) clearance of its Colli-Pee(TM)- Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche's tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) and run on Roche's cobas(R) 5800, 6800, and 8800 molecular diagnostic systems. The FDA-cleared collection kit supports at-home self-collection of first-void urine, enabling convenient sample collection at-home or in any private setting for both male and female patients. This clearance marks a significant advancement in patient-centric diagnostics, combining OraSure's Colli-Pee(TM)- Dx Urine Collection Kit, which includes NucleoPrecision(TM) Technology, a proprietary chemistry for DNA and RNA stabilization, with Roche's cobas(R) high-throughput molecular testing capabilities. The Colli-Pee(TM)- Dx Urine Collection Kit uses innovative stabilization technology to make STI laboratory testing easier by allowing reliable, private at-home urine collection and maintaining urine sample integrity at ambient temperatures. It expands access for individuals constrained by mobility, geography, or other barriers; improves patient convenience; and makes population-level screening programs feasible for broader, previously underserved populations. Healthcare providers can now prescribe, and laboratories can now receive, self-collected urine specimens directly from patients' homes and process them seamlessly and at scale using Roche's cobas(R) automated laboratory platforms. The Colli-Pee(TM)- Dx Urine Collection Kit is designed to collect volumetric, first-void urine, ensuring optimal sample-to-preservative-ratio, a critical factor for STI detection, while offering a simple, non-invasive experience that prioritizes patient convenience and privacy. "This clearance connects people to care that is more accessible, convenient, private, and personalized. It showcases what's possible when you design solutions around real-life patient behavior," said Carrie Eglinton Manner, President and Chief Executive Officer of OraSure. "We are committed to delivering user-friendly tests and collection devices that can be conveniently used in decentralized settings, and this clearance reflects meaningful progress on our innovation roadmap." Enabling Scalable, Decentralized Testing With FDA clearance, laboratories and health systems can now deploy a fully validated mail-in workflow that supports high-volume molecular STI testing without invasive sample collection methods. The collaboration enables the convenience of at-home urine collection, improves reach to populations in need, and supports public health initiatives focused on early detection and treatment of STIs. The Colli-Pee(TM)- Dx Urine Collection Kit will be sold by OraSure subsidiary DNA Genotek. About OraSure Technologies OraSure Technologies, Inc. ("OraSure" and "OTI") transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI's portfolio of products is sold globally to clinical laboratories, hospitals, physicians' offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com. | Investor Contact: | Media Contact: | | Jason Plagman | Amy Koch | | Vice President, Investor Relations | Director, Corporate Communications | | [email protected] | [email protected] | | / | / | Forward Looking Statement This press release contains certain "forward-looking statements." Forward-looking statements are based on current expectations of future events and are not guarantees of future performance or results. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: uncertainty of commercial success; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; unexpected safety, quality or manufacturing issues; government regulation and unexpected regulatory actions or delays; ability to comply with applicable regulatory requirements; uncertainty relating to patent protection and potential patent infringement claims; impact of competitors, competing products and technology changes and patents obtained by competitors; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; impact of negative economic conditions; changes in behavior and spending patterns of purchasers; product efficacy or safety concerns resulting in product recalls or regulatory action; and changes to applicable laws and regulations. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure undertakes no duty to update these statements.